Cleveland Clinic received a $7.9 million five-year grant from the National Cancer Institute at the National Institutes of Health to form one of three national centers as part of the newly established Radiation Oncology-Biology Integration Network (ROBIN).
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma. Evidence-based recommendations outline the multidisciplinary planning and delivery techniques to manage this subset of central nervous system (CNS) tumors.
A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.
MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.
Radiation is an effective treatment for prostate cancer. Ronald D. Ennis, MD,Professor and Vice Chair of Network Integration and Quality, Department of Radiation Oncology at Rutgers Cancer Institute, along with Lara Hathout, MD, FRCPC, radiation oncologist and director of Brachytherapy at Rutgers Cancer Institute and associate Professor of radiation oncology at Rutgers Robert Wood Johnson Medical School share more
Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
This special edition features oral presentations by MD Anderson researchers at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Oct. 24-27) on novel therapeutic and diagnostic approaches, including partial breast irradiation, evaluating PD-L1 levels as biomarkers to better predict response to immunotherapy, and deep learning and biomechanical models.
A new study shows that system-level changes to the way cancer care is delivered can also eliminate Black-white disparities in survival from early-stage lung and breast cancer. By identifying and addressing obstacles that kept patients from finishing radiation treatments for cancer, the intervention improved five-year survival rates for all patients and erased the survival gap between Black and white patients. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
High-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases, according to a new study. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
People with liver cancer awaiting transplantation could benefit from non-invasive radiation treatments but are rarely given this therapy, according to a new analysis of U.S. national data. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
New research from Washington University School of Medicine in St. Louis suggests that radiation therapy can reprogram heart muscle cells to what appears to be a younger state, fixing electrical problems that cause a life-threatening arrhythmia without the need for a long-used, invasive procedure.
Think of it like radio making way for television. Image-guided radiation therapy has evolved to include the ability to track tumors in real time during treatment. It’s improving cure rates and limiting side effects for a growing number of cancer patients.
Researchers from Cleveland Clinic, Case Western Reserve University School of Medicine, and Moffitt Cancer Center have found that the genomic adjusted radiation dose (GARD) may be used to personalize radiotherapy (RT) to maximize the therapeutic effect of a given physical RT dose. This research was published Aug. 4 in The Lancet Oncology journal.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on radiation therapy for soft tissue sarcoma. Recommendations outline optimal radiation dosing, techniques and treatment planning, with a focus on preserving long-term functionality through individualized care.
In response to consecutive weeks of significant proposed Medicare payment cuts to radiation oncology cancer care, Thomas J. Eichler, MD, Chair of American Society for Radiation Oncology (ASTRO), issued the following statement.
Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 63rd Annual Meeting, which will return to an in-person conference at McCormick Place West in Chicago, October 24-27, 2021. Media resources and registration are available at www.astro.org/astro2021press, and general registration is available at www.astro.org/annualmeeting.
A new study led by Washington University School of Medicine in St. Louis provides new guidance on the treatment of medulloblastoma, a pediatric brain cancer. Some aspects of radiation therapy may be reduced while still providing effective treatment.
The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.
Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanced disease than before the COVID-19 pandemic, according to a new survey from the American Society for Radiation Oncology (ASTRO). The survey fielded in early 2021 also found that treatment postponements and deferrals have largely subsided.
Targeted radiation is often used to study and treat diverse cancer types. A multidisciplinary research team based at the University of Chicago Medicine has recently focused on a type of cell that releases a protein that enhances resistance to cancer therapies and promotes tumor progression.
A new study finds that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. But coupling immunotherapy with radiotherapy to the liver in mice restored the immune cell function and led to better outcomes.
Radiation oncologists across the country will meet virtually with members of Congress this week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based health care for people with cancer. The doctors will meet with Congressional leaders and staff as part of the American Society for Radiation Oncology (ASTRO) virtual Advocacy Day, which will take place November 19-20, 2020.
A phase III trial from India shows that an advanced radiation therapy technique leads to fewer gastrointestinal side effects in women who receive radiation after undergoing hysterectomy for cervical cancer. Findings from the PARCER trial (NCT01279135) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the case for radiation therapy as a treatment for cancer that has begun to spread throughout the body. Findings of the SAFRON II trial (NCT01965223) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
A new study shows using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. Findings from the Canadian phase II/III trial (NCT02512965) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Results of a new randomized phase III trial suggest that stereotactic radiosurgery (SRS) should replace whole brain radiation therapy (WBRT) as the standard of care for patients with four or more brain metastases. Results from the clinical trial (NCT01592968) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds. Findings from the randomized phase II/III EMPIRE-1 trial (NCT01666808) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Radiation therapy for breast cancer can be grueling and disruptive, stretching out for as long as five to seven weeks, and often requiring extended time off from work or away from home. But research over the past decade, as well as new technology and innovations at Mayo Clinic, has led to treatment alternatives that are shorter, more targeted and just as effective.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance for physicians who use radiation therapy to treat patients with locally advanced rectal cancer. Recommendations outline indications and best practices for pelvic radiation treatments, as well as the integration of radiation with chemotherapy and surgery for stage II-III disease. The guideline, which replaces ASTRO’s 2016 guidance for rectal cancer, is published in Practical Radiation Oncology.
The American Society for Radiation Oncology (ASTRO) announced today the press program for its 2020 Annual Meeting, which will feature studies on cancer treatment advances and discussions of topical issues including COVID-19. Researchers will present their findings via live webcasts on October 26 and 27. Register for press access at www.astro.org/annnualmeetingpress.
Radiation oncologists today expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States. Leaders of the American Society for Radiation Oncology (ASTRO) urge eviCore, a radiation oncology benefits management company, to halt and make meaningful changes to a new policy for radiation therapy coverage. Under the new policy, EviCore mandates that most breast and prostate cancer treatments use a shorter, hypofractionated radiation therapy regimen even if it runs counter to a physician’s clinical recommendation.
While heat shock protein 90 inhibitors have shown limited benefit in directly treating cancer, low doses may improve the efficacy of radiotherapy, a new study finds.
The American Society for Radiation Oncology’s (ASTRO) 62nd Annual Meeting, will be held October 25-28 via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center. Media resources are available at www.astro.org/astro2020press.
For patients with brain arteriovenous malformations, not having surgery or getting radiation therapy can result in an almost 70-per-cent lower risk of having a stroke or dying, reseachers find.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline outlines indications and best practices for EBRT and brachytherapy in postoperative and definitive settings, and it also addresses chemotherapy and surgery when used in combination with radiation. The guideline is published online in Practical Radiation Oncology.
Despite facing challenges such as limited access to PPE during the COVID-19 outbreak, radiation oncology clinics quickly implemented safety enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO). All 222 physician leaders in the survey collected April 16-30 said their practices continued to provide radiation therapy, yet 85% also reported declines in patient visits, and by an average of one-third.
Radiation is one of the oldest and most common therapies for cancer, and typically is delivered locally, or to specific targeted sites in the body. While it has long been thought that locally-delivered radiation therapy typically does not help to shrink tumors outside the field of irradiation, new preclinical research from a team at Roswell Park Comprehensive Cancer Center suggests a strategy for significantly increasing both the local and distant, or “abscopal,” effects of radiation. Results of the study, which was led by Elizabeth Repasky, PhD, have been newly published in Nature Communications.
A secondary analysis of the Radiation Therapy Oncology Group (RTOG) 9601 phase 3 randomized clinical trial finds the benefit of hormone therapy varies depending on a patient’s PSA level.
An international team issues recommendations for managing prostate cancer patients during the COVID-19 pandemic
Researchers at Washington University School of Medicine in St. Louis have identified a way to make radiation therapy for colorectal cancer more effective by inhibiting a protein found in cancer cells in the gut.
A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.
Baylor Scott & White Health’s Glenda Tanner Vasicek Cancer Treatment Center (VCTC) – Temple announces construction of a new radiation oncology facility that will benefit Central Texas patients being treated for cancer. With new radiation treatment equipment and more room for procedures, the facility will be able to treat up to 70 patients per day.
More than half of all cancer patients undergo radiation therapy and the dose is critical. Too much and the surrounding tissue gets damaged, too little and the cancer cells survive.
Cancer patients may one day be able to get their entire course of radiation therapy in less than a second rather than coming in for treatment over the course of several weeks, and researchers in the Abramson Cancer Center of the University of Pennsylvania have taken the first steps toward making it a reality
Cancer patients who receive high-tech proton therapy experience similar cure rates and fewer serious side effects compared with those who undergo traditional X-ray radiation therapy, according to a study led by Washington University School of Medicine in St. Louis and the Perelman School of Medicine at the University of Pennsylvania.
A new clinical guideline from ASTRO provides recommendations on the use of radiation therapy to treat patients diagnosed with the most common types of skin cancers. The guideline details when radiation treatments are appropriate as stand-alone therapy or following surgery for BCC and cSCC, and it suggests dosing and fractionation.
Investigators at Rutgers Cancer Institute of New Jersey conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates along with good-to-excellent patient-reported cosmetic outcomes.